Results 21 to 30 of about 874,981 (155)

Immunogenicity to biological drugs in psoriasis and psoriatic arthritis

Clinics, 2021
Monoclonal antibodies or fusion proteins, defined as biological drugs, have modified the natural history of numerous immune-mediated disorders, allowing the development of therapies aimed at blocking the pathophysiological pathways of the disease ...
Fernando Valenzuela, Rodrigo Flores
doaj   +1 more source

Impact of anti-TNF and anti-IL-12/IL-23 antibody therapy on periodontal inflammation and gingival crevicular fluid IL-6 in patients with inflammatory bowel diseases [PDF]

Frontiers in Immunology
IntroductionPeriodontitis prevalence is elevated in patients with inflammatory bowel diseases (IBD). Biological therapies targeting cytokines such as tumor necrosis factor (TNF) and interleukin-12/23 (IL-12/23) are central to IBD management, yet their ...
Nicole Neurath, Nicole Neurath, Nicole Neurath, Andre Jefremow, Andre Jefremow, Selina Sitte, Selina Sitte, Hady Haririan, Raja Atreya, Raja Atreya, Marco Kesting, Marco Kesting   +11 more
doaj   +2 more sources

Ustekinumab

Turkderm Turkish Archives of Dermatology and Venereology, 2022
Ustekinumab is an antagonistic human monoclonal immunoglobulin G1 antibody that targets p40, a common subunit of interleukin-12 (IL-12) and IL-23. In clinical trials, 66-81% of the patients using ustekinumab achieved a PASI75 response.
Murat Borlu
doaj   +1 more source

Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis

European Journal of Dermatology, 2021
Guselkumab, a subcutaneously administered fully human IgG1λ monoclonal antibody that selectively inhibits the p19 subunit of interleukin 23, is approved in both the USA and the EU for the treatment of adult patients with moderate-to-severe plaque psoriasis.
Chiricozzi A., Costanzo A., Fargnoli M. C., Malagoli P., Piaserico S., Amerio P., Argenziano G., Balato N., Bardazzi F., Bianchi L., Carrera C. G., Conti A., Dapavo P., De Simone C., Loconsole F., Lo Schiavo A., Malara G., Musumeci M. L., Parodi A., Peris K., Prignano F., Rongioletti F., Talamonti M., Potenza C.   +23 more
openaire   +11 more sources

Noncanonical conformation of CDR L1 in the anti-IL-23 antibody CNTO4088 [PDF]

Acta Crystallographica Section F Structural Biology and Crystallization Communications, 2010
CNTO4088 is a monoclonal antibody to human IL-23. The X-ray structure of the Fab fragment revealed an unusual noncanonical conformation of CDR L1. Most antibodies with the kappa light chain exhibit a canonical structure for CDR L1 in which residue 29 anchors the CDR loop to the framework.
Alexey, Teplyakov, Galina, Obmolova, Alison, Rogers, Gary L, Gilliland   +3 more
openaire   +2 more sources

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study

Psoriasis: Targets and Therapy, 2022
Matteo Megna, Luca Potestio, Gabriella Fabbrocini, Angelo Ruggiero Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, 80131, ItalyCorrespondence: Angelo Ruggiero, Section of Dermatology ...
Megna M, Potestio L, Fabbrocini G, Ruggiero A   +3 more
doaj  

IL‐23/IL‐17 immune axis mediates the imiquimod‐induced psoriatic inflammation by activating ACT1/TRAF6/TAK1/NF‐κB pathway in macrophages and keratinocytes

Kaohsiung Journal of Medical Sciences, 2023
The interleukin‐23 (IL‐23)/IL‐17 immune axis has been linked to the pathology of psoriasis, but how this axis contributes to skin inflammation in this disease remains unclear. We measured inflammatory cytokines associated with the IL‐23/IL‐17 immune axis
Wen‐Cheng Chen, Chang‐Hui Wen, Meng Wang, Zi‐Dan Xiao, Zhong‐Zhao Zhang, Chun‐Lan Wu, Ran Wu   +6 more
doaj   +1 more source

Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study

Reumatismo, 2020
The development of new biologic and targeted synthetic DMARDs can lead to good disease control. The aim of the present study was to assess the rate of remission and low disease activity, and the improvement of pain and function, in psoriatic arthritis ...
F.M. Perrotta, A. Delle Sedie, S. Scriffignano, P. Volpe, E. Cordisco, N. Milano, M. Gabini, E. Lubrano   +7 more
doaj   +1 more source

Characteristics of anti-IL-17/23 biologics-induced interstitial pneumonia in patients with psoriasis.

PLoS ONE, 2021
ObjectivesAnti-IL-17/23 biologics are increasingly used to treat psoriasis. We aimed to elucidate characteristics of drug-induced interstitial pneumonia (DIIP) caused by anti-IL-17/23 biologics.MethodsWe retrospectively analyzed the clinical data of ...
Hanae Miyagawa, Hiromichi Hara, Jun Araya, Shunsuke Minagawa, Takanori Numata, Yoshinori Umezawa, Akihiko Asahina, Hidemi Nakagawa, Kazuyoshi Kuwano   +8 more
doaj   +1 more source

Risankizumab for the Treatment of the Patients with Moderate to Severe Plaque Psoriasis During a 24-Week Period: Real-Life Experience

Clinical, Cosmetic and Investigational Dermatology, 2023
Melis Gönülal,1 Didem Didar Balcı,1 Serap Öztürkcan2 1Department of Dermatology, University of Health Sciences, Izmir Tepecik Training and Research Hospital, İzmir, Turkey; 2Department of Dermatology, Manisa Celal Bayar University Hafsa ...
Gönülal M, Balcı DD, Öztürkcan S
doaj